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Abstract
 
Background
 
Chronic plaque psoriasis is associated with overweight or
obesity. Anti–tumour necrosis factor-
 
α
 
 (anti-TNF-
 
α
 
) treatments are now
frequently used in psoriasis management. TNF-
 
α
 
 is deeply involved in body
weight homeostasis, which may be affected by TNF-
 
α
 
–targeted therapy.
 
Objective
 
To investigate whether anti-TNF-
 
α
 
 treatments is associated with
changes in body weight in patients with chronic plaque psoriasis.
 
Methods
 
We performed a retrospective controlled analysis comparing the
variations in body weight and body mass index (BMI) in three closed cohorts
of psoriatic patients during a 6-month treatment with etanercept (
 
N
 
 = 58),
infliximab (
 
N
 
 = 40) or methotrexate (
 
N
 
 = 43).
 
Results
 
We observed a body weight increment of 1.5 
 
±
 
 2.7 kg (mean 
 
±
 
 SD;
 
P
 
 = 0.0002) and 2.5 
 
±
 
 3.3 kg (
 
P = 
 
0.004) in patients treated with etanercept and
infliximab, respectively. In contrast, a non-significant change (0.6 
 
±
 
 1.4 kg;
 
P
 
 = 0.4) was measured in patients treated with methotrexate. The BMI
increased with 0.5 
 
±
 
 0.5 (
 
P = 
 
0.01) and 0.8 
 
±
 
 1 (
 
P = 
 
0.003) points in patients
treated with etanercept and infliximab, respectively, whereas it did not change
(< 0.2 
 
±
 
 0.5; 
 
P
 
 = 0.06) in patients treated with methotrexate. About one fourth
of patients experienced a 4- to 10-kg weight gain. Differences in body weight
variations among patients treated with anti-TNF-
 
α
 
 therapies and methotrexate
were statistically significant (
 
P = 
 
0.0005). We could not identify clinical para-
meters predicting this phenomenon.
 
Conclusions
 
Patients with psoriasis treated with long-term anti-TNF-
 
α
 
therapies may manifest a body weight gain. This effect should be taken into
account in the global approach to patients with psoriasis.
 
Introduction
 
Chronic plaque psoriasis is associated with obesity in
12.9% to 34% of cases.
 
1–4
 
 Although the directionality of
this positive correlation is still unclear, two studies suggest
that overweight and obesity appear after the onset of
psoriasis.
 
1,5
 
 In contrast, two other studies found a high
prevalence of obesity in patients with recent onset
psoriasis, suggesting that obesity precedes and may
represent a risk factor for psoriasis.
 
2,6
 
 Obesity is a strong
risk factor for hypertension and type 2 diabetes, and all of
these are important cardiovascular risk factors. Indeed, it
has been documented that there is an increased mortal-
ity from cardiovascular diseases in patients with severe
psoriasis, and psoriasis may confer an independent risk of
myocardial infarction especially in young patients.
 
7,8
 
Anti–tumour necrosis factor-
 
α
 
 (anti-TNF-
 
α
 
) treatments are
now frequently used in psoriasis management. TNF-
 
α
 
 is
deeply involved in body weight homeostasis, which may
be affected by TNF-
 
α
 
–targeted therapy. Recently, body
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weight gain has been reported both in patients with
spondyloarthropathy
 
9
 
 and patients with Crohn’s disease
 
10
 
treated with anti-TNF-
 
α
 
 inhibitors. We conducted a
retrospective cohort study aimed to see whether anti-
TNF-
 
α
 
 treatments are associated with changes in body
weight in patients with psoriasis.
 
Materials and methods
 
Study population
 
One hundred and forty-one psoriatic patients consecutively
admitted to the outpatients clinics of the University
Hospital of Verona were involved. The source population
of the study was people living in city of Verona or in the
neighbourhood. Patients were affected by chronic plaque
psoriasis diagnosed according to clinical criteria. Patients
with psoriatic arthritis diagnosed according to the
CASPAR criteria were excluded.
 
11
 
 All subjects were visited
by a dermatologist who registered demographical, bio-
metrical and the other relevant data on a case report
form. Visits were scheduled at baseline and every 2 months
for patients treated with methotrexate and etanercept,
whereas visits were scheduled at each infusion for
patients receiving infliximab. Relevant data collected
included age, gender, weight, height, body mass index
(BMI), age of psoriasis onset, type and severity of psoriasis
and concomitant medications. BMI was calculated as
weight (kg)/height (cm
 
2
 
). Severity of psoriasis was assessed
according to the Psoriasis Area and Severity Index
(PASI) and body surface area (BSA). Venous samples were
taken at baseline visit and every 2 months after the
subjects had fastened overnight (at least 8 h). Patients
were treated with methotrexate, etanercept or infliximab,
respectively. The indications for anti-TNF-
 
α
 
 treatments
were chronic plaque psoriasis with a PASI score and a
BSA% involvement of more than 10 and resistance or
intolerance to methotrexate, cyclosporin, acitretin or photo-
therapy. Etanercept and infliximab were randomly assigned
to patients resistant or intolerant to methotrexate, which
was used as the first choice drug. All patients who received
etanercept or infliximab were biological therapy naïve.
Doses of systemic drugs used were as follows: methotrexate
was given 15 mg once weekly by intramuscular injection;
etanercept 25 mg twice weekly by subcutaneous injections;
and infliximab 5 mg/kg at week 0, 2, 6 and then every
8 weeks by intravenous infusion.
 
Statistical analysis
 
Analysis was made using the STATA (version 6.0 Stata-
Corp LP, College Station, TX, USA) and Graphpad (version
4.0 GraphPad Software, El Camino Real, San Diego, CA, USA)
software packages. Standard descriptive statistics, such as
mean and standard deviation, were computed. Differences
in body weight, BMI, PASI score, plasma glucose, total
cholesterol and triglycerides within groups were compared
using Wilcoxon’s signed rank sum test. Differences
between groups were compared using 
 
ANOVA
 
 test corrected
using the Bonferroni formula. Associations between body
weight increment and categorical variables (age and
gender) were tested by Fisher exact test, whereas 
 
t
 
-test
was used for continuous variables (BMI, body weight,
PASI score and serum lipids). All 
 
P
 
-values are two sided,
and 
 
P
 
 < 0.05 was considered statistically significant.
 
Results
 
Forty-three patients treated with methotrexate, 58
patients with etanercept and 40 patients with infliximab
were included in the study (Table 1). At enrolment, no
significant differences in age, sex, body weight and BMI
were present among the three groups of patients. Psoriasis
duration was also similar in the three groups, whereas
patients treated with methotrexate had a lower PASI
score. At 6 months, we observed a mean body weight
increment of 1.5 
 
±
 
 2.7 kg (
 
±
 
 SD; 
 
P
 
 = 0.0002) and 2.5 
 
±
 
 3.3 kg
(
 
P = 
 
0.004) in patients treated with etanercept and in-
fliximab, respectively. In contrast, a non-significant change
(–0.6 
 
±
 
 1.4 kg; 
 
P
 
 = 0.4) was measured in patients treated
with methotrexate. In particular, in the etanercept cohort,
6 patients (10.3%) lose weight; 15 patients (25.8%)
did not show body weight variation; 24 patients (41.3%)
increased weight by 1 to 3 kg; and 13 patients (22.4%)
increased weight by 4 to 10 kg. In the cohort of infliximab,
3 patients (7.5%) lose weight, 7 (17.5%) did not show
body weight change; 19 patients (47.5%) increased
weight by 1 to 3 kg; and 11 patients (27.5%) increased
weight by 4 to 10 kg. In the methotrexate cohort, 8
patienta (18.6%) lose weight; 32 patients (74.4%) did
not show body weight variation; and 3 patients (6.9%)
increased weight by 1 to 3 kg. The BMI increased with
0.5 
 
±
 
 0.5 (mean 
 
±
 
 SD; 
 
P
 
 = 0.01) and 0.8 
 
±
 
 1 (
 
P = 
 
0.003)
points in patients treated with etanercept and infliximab,
respectively, whereas it did not change (–0.2 
 
±
 
 0.5; 
 
P
 
 =
0.06) in patients treated with methotrexate. Differences in
body weight variations among patients treated with anti-
TNF-
 
α
 
 therapies and methotrexate were statistically signific-
ant (
 
P = 
 
0.0005). The relative risk of gaining 
 
≥ 
 
5 kg of body
weight among patients exposed to anti-TNF-
 
α
 
 treatments
was 4.3 times higher than in patients exposed to metho-
trexate. There were no differences in body weight mean
increment according to age group (> 50 or < 50 years old),
gender, BMI classes and psoriasis severity (PASI score > 10
or < 10) at enrolment. After 6 months of treatment, mean
PASI score was decreased by 47.1% (
 
P = 
 
0.0002), 74.5%
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(
 
P = 
 
0.0001) and 88.8% (
 
P = 
 
0.0001) in patients treated
with methotrexate, etanercept and infliximab, respectively.
No significant changes in fasting plasma glucose, total
cholesterol and triglycerides mean levels were observed in
any of the three groups as well as no severe adverse
events.
 
Discussion
 
These data show that patients with psoriasis receiv-
ing anti-TNF-
 
α
 
 therapy, but not those treated with
methotrexate, may manifest a significant body weight
gain after 6 months of treatment. A relevant increase
(4–10 kg) in body weight was observed in about 25% of
patients treated with etanercept or infliximab. We could
not identify clinical parameters predicting this phenomenon.
No patients referred modifications in eating behaviour
and physical activity and/or increment of appetite or
anorexia. We did not study body composition by bio-
impedance, whereas Briot 
 
et al
 
. reported an increase in
body weight, bone mineral density and in lean mass, but
not in fat mass, in parallel with an increase in insulin-like
growth factor-1 in patients with spondyloarthropathies
(including psoriatic arthritis) receiving a 1-year anti-
TNF-
 
α
 
 treatment.
 
9
 
 In contrast, no studies have reported
body weight gain in patients with rheumatoid arthritis
after anti-TNF-
 
α
 
 therapy. Therefore, it is possible that the
different type of inflammation/immune response or the
genetic background (usually patients with rheumatoid
arthritis are lean) is important in determining whether
anti-TNF-
 
α
 
 can favour weight gain. Our study has several
limitations, including the possible selection of the more
severe psoriatic patients in the anti-TNF-
 
α
 
–treated group.
Although baseline PASI scores were not significantly
different in the three groups, etanercept and infliximab
were randomly assigned to patients resistant or intolerant
to methotrexate or other traditional systemic therapies,
which were used as the first-line therapy.
The reason for the increased weight among patients
treated with anti-TNF-
 
α
 
 agents is not known. TNF-
 
α
 
/
cachectin 
 
α
 
 is deeply involved in body weight homeostasis
by favouring muscle cell catabolism both in physiological
and pathological conditions.
 
12–14
 
 Anti-TNF-
 
α
 
 treatment
may have and indirect positive effect on lean mass
throughout the general health improvement of patients,
leading to increase of appetite. Indeed, TNF-
 
α
 
 can
influence appetite through modulation of leptin release
from adipocytes.
 
15
 
 Franchimont 
 
et al
 
. observed that a
4-week infliximab treatment induced a body weight and
an increase in leptin serum levels in patients with Crohn’s
disease.
 
10
 
 We did not observe differences in plasma trigly-
cerides and cholesterol levels following any treatments,
although significant elevation in plasma lipids have been
reported in some patients with rheumatoid arthritis or
psoriasis treated with TNF-
 
α
 
 inhibitors.
 
16,17
 
 On the other
hand, recent reports suggest TNF-
 
α
 
 inhibitors can improve
Table 1 Study population. Descriptive characteristic of the three groups of patients
MTX
Δwithin 
group* Etanercept
Δwithin 
group* Inﬂiximab
Δwithin 
group*
Δbetween 
groups†
Number 43 58 40
Sex, F/M 17/26 19/39 12/28 0.5
Age (y), mean ± SD 53.1 ± 12.7 50.2 ± 11.1 46.8 ± 11.2 0.7
Psoriasis duration (y), mean ± SD 18.6 ± 12  22 ± 12.9 17.5 ± 13.4 0.2
Body weight at enrolment, mean ± SD 81.0 ± 12.6 80.1 ± 16.2 79.2 ± 15.2 0.9
Body weight at month 6, mean ± SD 79.2 ± 13.9 0.4 81.7 ± 16.4 0.0002 81.8 ± 16.9 0.004 0.6
BMI at enrolment, mean ± SD 27.4 ± 3.6 27.6 ± 5 26.5 ± 3.5 0.6
BMI at month 6, mean ± SD 27.3 ± 3.8 0.06 28.1 ± 5 0.01 27.3 ± 3.8 0.003 0.7
PASI at enrolment, mean ± SD 8.2 ± 3.1 18.8 ± 7.4 17.7 ± 7.3 0.0001‡; 0.6§
PASI at month 6, mean ± SD 4.3 ± 6 0.0002 4.8 ± 4.7 0.0001 2.1 ± 3.2 0.0001
PASI mean improvement percentage 47.6 74.5 88.8 0.0004‡; 0.02§
Total cholesterol level at enrolment, mean ± SD  234 ± 16.8  233 ± 15.1 235.3 ± 14.2 0.8‡; 0.7§
Total cholesterol level at month 6, mean ± SD  236 ± 18.1 0.4  235 ± 17.3 0.5  237 ± 16.9 0.6
Triglycerides levels at enrolment, mean ± SD  170 ± 17.8  168 ± 18.3  172 ± 18.1
Triglycerides levels at month 6, mean ± SD  175 ± 18.9 0.2  167 ± 19.4 0.7  170 ± 16.2 0.09
*Differences within groups were compared using Wilcoxon’s signed rank sum test;
†Differences between groups were compared using ANOVA test corrected using Bonferroni formula;
‡Methotrexate vs. etanercept or inﬂiximab;
§Etanercept vs. inﬂiximab.
MTX, methotrexate.
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metabolic parameters and reduce cardiovascular risk
factors. In particular, TNF-α blockade has been shown to
improve insulin resistance, reduce serum levels of C-
reactive protein and carotid intima-media thickness in
patients with rheumatoid arthritis.18,19
The potential effect of anti-TNF-α treatments on body
weight should be taken into account in the long-term
their use in overweight and obese psoriatic patients.
References
1 Herron MD, Hinckley M, Hoffman MS et al. Impact of 
obesity and smoking on psoriasis presentation and 
management. Arch Dermatol 2005; 141: 1527–1534.
2 Naldi L, Chatenoud L, Linder D et al. Cigarette smoking, 
body mass index, and stressful life events as risk factors for 
psoriasis: results from an Italian case-control study. J Invest 
Dermatol 2005; 125: 61–67.
3 McGowan JW, Pearce DJ, Chen J, Richmond D, 
Balkrishnan R, Feldman SR. The skinny on psoriasis and 
obesity. Arch Dermatol 2005; 141: 1601–1602.
4 Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, 
Gelfand JM. Prevalence of cardiovascular risk factors in 
patients with psoriasis. J Am Acad Dermatol 2006; 55: 
829–835.
5 Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is 
associated with lipid abnormalities at the onset of skin 
disease. J Am Acad Dermatol 2006; 54: 614–621.
6 Mallbris L, Larsson P, Bergqvist S, Vingard E, Granath F, 
Stahle M. Psoriasis phenotype at disease onset: clinical 
characterization of 400 adult cases. J Invest Dermatol 2005; 
124: 499–504.
7 Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, 
Troxel AB. Risk of myocardial infarction in patients with 
psoriasis. JAMA 2006; 296: 1735–1741.
8 Ludwig RJ, Herzog C, Rostock A et al. Psoriasis: a possible 
risk factor for development of coronary artery calcification. 
Br J Dermatol 2007; 156: 271–276.
9 Briot K, Garnero P, Le Henanff A, Dougados M, Roux C. 
Body weight, body composition, and bone turnover changes 
in patients with spondyloarthropathy receiving anti-tumour 
necrosis factor alpha treatment. Ann Rheum Dis 2005; 64: 
1137–1140.
10 Franchimont D, Roland S, Gustot T et al. Impact of 
infliximab on serum leptin levels in patients with Crohn’s 
disease. J Clin Endocrinol Metab 2005; 90: 3510–3516.
11 Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, 
Mielants H; CASPAR Study Group. Classification criteria 
for psoriatic arthritis: development of new criteria from 
a large international study. Arthritis Rheum 2006; 54: 
2665–2673.
12 Roubenoff R, Roubenoff RA, Cannon JG et al. Rheumatoid 
cachexia: cytokine-driven hypermetabolism accompanying 
reduced body cell mass in chronic inflammation. J Clin Invest 
1994; 93: 2379–2386.
13 Walsmith J, Abad L, Kehayias J, Roubenoff R. Tumor 
necrosis factor-alpha production is associated with less body 
cell mass in women with rheumatoid arthritis. J Rheumatol 
2004; 31: 23–29.
14 Visser M, Pahor M, Taaffe DR et al. Relationship of 
interleukin-6 and tumor necrosis factor-alpha with muscle 
mass and muscle strength in elderly men and women: the 
Health ABC Study. J Gerontol a Biol Sci Med Sci 2002; 57: 
326–332.
15 Kirchgessner TG, Uysal KT, Wiesbrock SM, Marino MW, 
Hotamisligil GS. Tumor necrosis factor-alpha contributes to 
obesity-related hyperleptinemia by regulating leptin 
release from adipocytes. J Clin Invest 1997; 100: 
2777–2782.
16 Sattar N, Crompton P, Cherry L, Kane D, Lowe G, 
McInnes IB. Effects of tumor necrosis factor blockade on 
cardiovascular risk factors in psoriatic arthritis: 
a double-blind, placebo-controlled study. Arthritis Rheum 
2007; 56: 831–839.
17 Seriolo B, Paolino S, Sulli A, Fasciolo D, Cutolo M. Effects of 
anti-TNF-alpha treatment on lipid profile in patients with 
active rheumatoid arthritis. Ann N Y Acad Sci 2006; 1069: 
414–419.
18 Porto FD, Lagana B, Lai S et al. Response to anti-tumour 
necrosis factor alpha blockade is associated with 
reduction of carotid intima-media thickness in patients 
with active rheumatoid arthritis. Rheumatology (Oxford) 
2007.
19 Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK. 
Effects of etanercept in patients with the metabolic 
syndrome. Arch Intern Med 2006; 166: 902–908.
